Ingenuity’s Path Designer is Selected as Best New Product By Life Science Community at 2008 Molecular Medicine Conference

Redwood City, CA – March 31, 2008 – Ingenuity Systems, the leading provider of information solutions for life science researchers, announced today that Path Designer, the new pathway publishing tool in IPA 6, was selected as the Best New Product by the scientific community in attendance at the Molecular Medicine Tri-Conference in San Francisco. Path Designer enables researchers to create customized, publication-quality graphics to more clearly communicate their experimental findings and scientific hypotheses. Path Designer offers a distinct advantage to users because the graphics remain interactive, so new information can be added and the original knowledge used to build the pathway remains accessible.

“We are delighted to have won this award,” stated Brigitte Ganter, Director of Product Management at Ingenuity Systems. “IPA’s development has always been customer-centric, and we developed Path Designer in response to our to customers’ need to effectively communicate their scientific findings in a visually compelling and meaningful manner. We are honored to receive this community-chosen award and appreciate the strong support from the IPA user community in designing the product.”

“Path Designer is unique for several reasons,” commented Ramon Felciano, Ph.D., CTO and Vice President, Research at Ingenuity Systems. “It provides the user with flexibility in how they represent different parts of pathways and networks. With this sort of control, researchers can modify the representation of drugs, genes, molecules, or relationships to clearly demonstrate their membership in various pathways, signatures, or disease processes. More importantly, the pathway remains dynamic, which means that researchers can continue to access and use Ingenuity’s uniquely structured knowledge base of literature findings while adding their own proprietary insights. There really is no better way to use pathways to illustrate key results and hypotheses to colleagues.”

About IPA
IPA is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA’s search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of peer-reviewed journals.

About Ingenuity Systems®
Ingenuity Systems is a leading provider of information solutions for the exploration, interpretation, and analysis of life science information. All of Ingenuity’s products and services have one common goal — to help life science researchers generate maximum value from all types of biological and chemical knowledge. Ingenuity offers a broad and flexible range of solutions that can be tailored to needs of various clients, including academic and therapeutic area researchers, computational biologists and informatics departments, and suppliers in the life sciences industry. All of the products leverage Ingenuity’s knowledge base, the largest data base of its kind, which houses the biological and chemical relationships extracted from scientific literature. The information is uniquely structured so scientists can ask complex biological questions to gain rapid insight into their experimental data or create relevant biological models to move forward in their research. Today, Ingenuity’s solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, and academic research institutions worldwide. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, Australia, and Japan.